Autoimmune cell therapy and T-cell engager trial starts vs Gene editing trial starts

In 2025, autoimmune cell therapy and T-cell engager trial starts worldwide stood at 112, against 35 for gene editing trial starts.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Autoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts

Unit: count · 12 observations

2 series · one axis
Autoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts: GlobalAutoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts. 2 indicators on one axis: Autoimmune cell therapy and T-cell engager trial starts, Gene editing trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Autoimmune cell therapy and T-cell engager trial starts 112 (2025); Gene editing trial starts 35 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 112 35 Autoimmune cell therapy and T-cell engager trial starts Gene editing trial starts
Autoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts: GlobalAutoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts. 2 indicators on one axis: Autoimmune cell therapy and T-cell engager trial starts, Gene editing trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Autoimmune cell therapy and T-cell engager trial starts 112 (2025); Gene editing trial starts 35 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 112 35 Autoimmune cell therapy and T-cell engager trial starts Gene editing trial starts
Autoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts: GlobalAutoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts. 2 indicators on one axis: Autoimmune cell therapy and T-cell engager trial starts, Gene editing trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Autoimmune cell therapy and T-cell engager trial starts 112 (2025); Gene editing trial starts 35 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 112 35 Autoimmune cell therapy and T-cell engager trial starts Gene editing trial starts
View the underlying data
Autoimmune cell therapy and T-cell engager trial starts and Gene editing trial starts: Global
Indicator Period Type Value
Autoimmune cell therapy and T-cell engager trial starts 2025 Actual 112
Autoimmune cell therapy and T-cell engager trial starts 2024 Actual 91
Autoimmune cell therapy and T-cell engager trial starts 2023 Actual 17
Autoimmune cell therapy and T-cell engager trial starts 2022 Actual 6
Autoimmune cell therapy and T-cell engager trial starts 2021 Actual 7
Autoimmune cell therapy and T-cell engager trial starts 2020 Actual 2
Gene editing trial starts 2025 Actual 35
Gene editing trial starts 2024 Actual 40
Gene editing trial starts 2023 Actual 27
Gene editing trial starts 2022 Actual 23
Gene editing trial starts 2021 Actual 17
Gene editing trial starts 2020 Actual 14

Shared periods

Side by side

6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Autoimmune cell therapy and T-cell engager trial starts Gene editing trial starts
2020 2 ClinicalTrials.gov 14 ClinicalTrials.gov
2021 7 ClinicalTrials.gov 17 ClinicalTrials.gov
2022 6 ClinicalTrials.gov 23 ClinicalTrials.gov
2023 17 ClinicalTrials.gov 27 ClinicalTrials.gov
2024 91 ClinicalTrials.gov 40 ClinicalTrials.gov
2025 112 ClinicalTrials.gov 35 ClinicalTrials.gov

Provenance

Where these numbers come from

Autoimmune cell therapy and T-cell engager trial starts

Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Gene editing trial starts

Count of interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related